- Home
- NPFD vs XERS Comparison
NPFD vs XERS Comparison
Compare NPFD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- XERS
- Stock Information
- Founded
- NPFD 2021
- XERS 2005
- Country
- NPFD United States
- XERS United States
- Employees
- NPFD N/A
- XERS N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- NPFD Finance
- XERS Health Care
- Exchange
- NPFD Nasdaq
- XERS Nasdaq
- Market Cap
- NPFD 455.5M
- XERS 526.3M
- IPO Year
- NPFD N/A
- XERS 2018
- Fundamental
- Price
- NPFD $18.75
- XERS $5.07
- Analyst Decision
- NPFD
- XERS Strong Buy
- Analyst Count
- NPFD 0
- XERS 6
- Target Price
- NPFD N/A
- XERS $5.92
- AVG Volume (30 Days)
- NPFD 64.7K
- XERS 4.7M
- Earning Date
- NPFD 01-01-0001
- XERS 03-06-2025
- Dividend Yield
- NPFD 6.28%
- XERS N/A
- EPS Growth
- NPFD N/A
- XERS N/A
- EPS
- NPFD N/A
- XERS N/A
- Revenue
- NPFD N/A
- XERS $203,070,000.00
- Revenue This Year
- NPFD N/A
- XERS $31.75
- Revenue Next Year
- NPFD N/A
- XERS $21.09
- P/E Ratio
- NPFD N/A
- XERS N/A
- Revenue Growth
- NPFD N/A
- XERS 23.89
- 52 Week Low
- NPFD $14.50
- XERS $1.69
- 52 Week High
- NPFD $18.07
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- NPFD 44.25
- XERS 56.26
- Support Level
- NPFD $18.75
- XERS $4.33
- Resistance Level
- NPFD $18.98
- XERS $6.07
- Average True Range (ATR)
- NPFD 0.14
- XERS 0.31
- MACD
- NPFD 0.01
- XERS -0.03
- Stochastic Oscillator
- NPFD 47.73
- XERS 41.14
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.